当前位置: 首页 >> 检索结果
2869. WHO-Lancet Global Series on health and the arts.
作者: Stephen Clift.;Arne Bathke.;Helena Daffern.;Christina Davies.;Katarzyna Grebosz-Haring.;Mette Kaasgaard.;J Matt McCrary.;George Musgrave.;Leonhard Thun-Hohenstein.
来源: Lancet. 2024年403卷10434期1335页 2874. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations.
2876. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
作者: José Manuel Pérez-García.;Javier Cortés.;Manuel Ruiz-Borrego.;Marco Colleoni.;Agostina Stradella.;Begoña Bermejo.;Florence Dalenc.;Santiago Escrivá-de-Romaní.;Lourdes Calvo Martínez.;Nuria Ribelles.;Frederik Marmé.;Alfonso Cortés.;Cinta Albacar.;Geraldine Gebhart.;Aleix Prat.;Khaldoun Kerrou.;Peter Schmid.;Sofia Braga.;Serena Di Cosimo.;Maria Gion.;Gabriele Antonarelli.;Crina Popa.;Emilia Szostak.;Daniel Alcalá-López.;Petra Gener.;Jose Rodríguez-Morató.;Leonardo Mina.;Miguel Sampayo-Cordero.;Antonio Llombart-Cussac.; .
来源: Lancet. 2024年403卷10437期1649-1659页
PHERGain was designed to assess the feasibility, safety, and efficacy of a chemotherapy-free treatment based on a dual human epidermal growth factor receptor 2 (HER2) blockade with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer (EBC). It used an 18fluorine-fluorodeoxyglucose-PET-based, pathological complete response (pCR)-adapted strategy.
2878. The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
作者: Prasad S Kulkarni.;Anirudha Vyankatesh Potey.;Sandesh Bharati.;Anil Kunhihitlu.;Bharath Narasimha.;Sindhu Yallapa.;Abhijeet Dharmadhikari.;Vinay Gavade.;Chandrashekhar D Kamat.;Asha Mallya.;Annamraju D Sarma.;Sunil Goel.;Sambhaji S Pisal.;Cyrus S Poonawalla.;Rajaram Venkatesan.;Elizabeth Jones.;Amy Flaxman.;Young Chan Kim.;Andrew J Pollard.; .
来源: Lancet. 2024年403卷10436期1554-1562页
Enteric fever caused by Salmonella enterica Typhi and Salmonella Paratyphi A is an important public health problem, especially in low-income and middle-income countries with limited access to safe water and sanitation. We present results from, to our knowledge, the first ever human study of a bivalent paratyphoid A-typhoid conjugate vaccine (Sii-PTCV).
2879. Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3 obesity: a population-based cohort study.
作者: Kari Johansson.;Lisa M Bodnar.;Olof Stephansson.;Barbara Abrams.;Jennifer A Hutcheon.
来源: Lancet. 2024年403卷10435期1472-1481页
There are concerns that current gestational weight gain recommendations for women with obesity are too high and that guidelines should differ on the basis of severity of obesity. In this study we investigated the safety of gestational weight gain below current recommendations or weight loss in pregnancies with obesity, and evaluated whether separate guidelines are needed for different obesity classes.
|